Lin Qin, Yang Rong-shui, Sun Long, Li Yi-min, Wang Li-chen, Dai Ming-ming, Luo Zuo-ming, Zhao Long, Wu Hua
Department of Radiation Oncology, Xiamen University, Xiamen, China.
Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):356-9.
The primary aim of this prospective study was to use serial (18)F-FDG PET-CT imaging to evaluate the trend of the tumor's maximum standardized uptake value (SUVmax) during radiotherapy (RT) for patients with nasopharyngeal carcinoma (NPC), and to explore the possibility of early evaluation of the tumor bio-metabolic response during radiotherapy.
Sixty patients with biopsy-proven primary NPC were prospectively enrolled into the study. All patients underwent four (18)F-FDG PET-CT scans: one initial scan before RT/cisplatin based concurrent chemoradiotherapy, at the point of 50 Gy during RT, the end of RT, and one month after RT, respectively. Tumor (18)F-FDG uptake was analyzed according to the World Health Organization pathological type.
There was a significant difference (P < 0.001) of the mean of SUVmax of the primary site among pretreatment (11.20 ± 5.37) and posttreatment at the dose of 50 Gy (3.50 ± 1.59), at the end of RT (3.05 ± 1.56) and one month after RT (2.52 ± 1.46). There was also a significant difference (P < 0.001) of the mean of SUVmax of neck node site. However, there was a significant difference of the SUVmax between histological WHO type IIb and type IIa in the primary site (P = 0.046) [(67 ± 19)% reduction at dose 50 Gy for type IIb vs. (55 ± 24)% for type IIa] but not in the lymph nodes.
Early PET scan during or right after RT instead of conventional 3 months interval after RT is indicated to evaluate the tumor response and to develop individualized adaptive radiotherapy in NPC. Our next study will attempt to demonstrate the results based on long-term follow-up data.
本前瞻性研究的主要目的是利用系列(18)F-FDG PET-CT成像评估鼻咽癌(NPC)患者放疗(RT)期间肿瘤最大标准化摄取值(SUVmax)的变化趋势,并探讨放疗期间早期评估肿瘤生物代谢反应的可能性。
前瞻性纳入60例经活检证实为原发性NPC的患者。所有患者均接受4次(18)F-FDG PET-CT扫描:分别在RT/基于顺铂的同步放化疗前进行1次初始扫描、RT剂量达50 Gy时、RT结束时以及RT结束后1个月。根据世界卫生组织病理类型分析肿瘤(18)F-FDG摄取情况。
原发部位SUVmax均值在预处理时(11.20±5.37)与50 Gy剂量时(3.50±1.59)、RT结束时(3.05±1.56)以及RT结束后1个月(2.52±1.46)之间存在显著差异(P<0.001)。颈部淋巴结部位SUVmax均值也存在显著差异(P<0.001)。然而,原发部位组织学WHO IIb型与IIa型之间的SUVmax存在显著差异(P = 0.046)[IIb型在50 Gy剂量时降低(67±19)%,IIa型为(55±24)%],但在淋巴结中无显著差异。
建议在RT期间或RT刚结束后尽早进行PET扫描,而非传统的RT后3个月间隔,以评估肿瘤反应并制定NPC的个体化适应性放疗方案。我们的下一步研究将尝试基于长期随访数据展示结果。